Literature DB >> 31593244

NITUMID: Nonnegative matrix factorization-based Immune-TUmor MIcroenvironment Deconvolution.

Daiwei Tang1, Seyoung Park2, Hongyu Zhao1.   

Abstract

MOTIVATION: A number of computational methods have been proposed recently to profile tumor microenvironment (TME) from bulk RNA data, and they have proved useful for understanding microenvironment differences among therapeutic response groups. However, these methods are not able to account for tumor proportion nor variable mRNA levels across cell types.
RESULTS: In this article, we propose a Nonnegative Matrix Factorization-based Immune-TUmor MIcroenvironment Deconvolution (NITUMID) framework for TME profiling that addresses these limitations. It is designed to provide robust estimates of tumor and immune cells proportions simultaneously, while accommodating mRNA level differences across cell types. Through comprehensive simulations and real data analyses, we demonstrate that NITUMID not only can accurately estimate tumor fractions and cell types' mRNA levels, which are currently unavailable in other methods; it also outperforms most existing deconvolution methods in regular cell type profiling accuracy. Moreover, we show that NITUMID can more effectively detect clinical and prognostic signals from gene expression profiles in tumor than other methods.
AVAILABILITY AND IMPLEMENTATION: The algorithm is implemented in R. The source code can be downloaded at https://github.com/tdw1221/NITUMID. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2020        PMID: 31593244      PMCID: PMC8215918          DOI: 10.1093/bioinformatics/btz748

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  25 in total

1.  Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.

Authors:  Yonit Lavin; Soma Kobayashi; Andrew Leader; El-Ad David Amir; Naama Elefant; Camille Bigenwald; Romain Remark; Robert Sweeney; Christian D Becker; Jacob H Levine; Klaus Meinhof; Andrew Chow; Seunghee Kim-Shulze; Andrea Wolf; Chiara Medaglia; Hanjie Li; Julie A Rytlewski; Ryan O Emerson; Alexander Solovyov; Benjamin D Greenbaum; Catherine Sanders; Marissa Vignali; Mary Beth Beasley; Raja Flores; Sacha Gnjatic; Dana Pe'er; Adeeb Rahman; Ido Amit; Miriam Merad
Journal:  Cell       Date:  2017-05-04       Impact factor: 41.582

2.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Authors:  Nadeem Riaz; Jonathan J Havel; Vladimir Makarov; Alexis Desrichard; Walter J Urba; Jennifer S Sims; F Stephen Hodi; Salvador Martín-Algarra; Rajarsi Mandal; William H Sharfman; Shailender Bhatia; Wen-Jen Hwu; Thomas F Gajewski; Craig L Slingluff; Diego Chowell; Sviatoslav M Kendall; Han Chang; Rachna Shah; Fengshen Kuo; Luc G T Morris; John-William Sidhom; Jonathan P Schneck; Christine E Horak; Nils Weinhold; Timothy A Chan
Journal:  Cell       Date:  2017-10-12       Impact factor: 41.582

3.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Authors:  Eliezer M Van Allen; Diana Miao; Bastian Schilling; Sachet A Shukla; Christian Blank; Lisa Zimmer; Antje Sucker; Uwe Hillen; Marnix H Geukes Foppen; Simone M Goldinger; Jochen Utikal; Jessica C Hassel; Benjamin Weide; Katharina C Kaehler; Carmen Loquai; Peter Mohr; Ralf Gutzmer; Reinhard Dummer; Stacey Gabriel; Catherine J Wu; Dirk Schadendorf; Levi A Garraway
Journal:  Science       Date:  2015-09-10       Impact factor: 47.728

Review 4.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

5.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

6.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

Authors:  Gabriela Bindea; Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Maximilian Waldner; Anna C Obenauf; Helen Angell; Tessa Fredriksen; Lucie Lafontaine; Anne Berger; Patrick Bruneval; Wolf Herman Fridman; Christoph Becker; Franck Pagès; Michael R Speicher; Zlatko Trajanoski; Jérôme Galon
Journal:  Immunity       Date:  2013-10-17       Impact factor: 31.745

7.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

8.  Robust enumeration of cell subsets from tissue expression profiles.

Authors:  Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Methods       Date:  2015-03-30       Impact factor: 28.547

9.  Estimation of immune cell content in tumour tissue using single-cell RNA-seq data.

Authors:  Max Schelker; Sonia Feau; Jinyan Du; Nav Ranu; Edda Klipp; Gavin MacBeath; Birgit Schoeberl; Andreas Raue
Journal:  Nat Commun       Date:  2017-12-11       Impact factor: 14.919

10.  Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data.

Authors:  Julien Racle; Kaat de Jonge; Petra Baumgaertner; Daniel E Speiser; David Gfeller
Journal:  Elife       Date:  2017-11-13       Impact factor: 8.140

View more
  4 in total

Review 1.  Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence.

Authors:  Ying Xu; Guan-Hua Su; Ding Ma; Yi Xiao; Zhi-Ming Shao; Yi-Zhou Jiang
Journal:  Signal Transduct Target Ther       Date:  2021-08-20

2.  SCADIE: simultaneous estimation of cell type proportions and cell type-specific gene expressions using SCAD-based iterative estimating procedure.

Authors:  Daiwei Tang; Seyoung Park; Hongyu Zhao
Journal:  Genome Biol       Date:  2022-06-15       Impact factor: 17.906

3.  A Cancer-Specific Qualitative Method for Estimating the Proportion of Tumor-Infiltrating Immune Cells.

Authors:  Huiting Xiao; Jiashuai Zhang; Kai Wang; Kai Song; Hailong Zheng; Jing Yang; Keru Li; Rongqiang Yuan; Wenyuan Zhao; Yang Hui
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

4.  Establishment of an Immune Cell Infiltration Score to Help Predict the Prognosis and Chemotherapy Responsiveness of Gastric Cancer Patients.

Authors:  Quan Jiang; Jie Sun; Hao Chen; Chen Ding; Zhaoqing Tang; Yuanyuan Ruan; Fenglin Liu; Yihong Sun
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.